Brazil possessed a vaccine in development, or so the president claimed
En los primeros días de marzo de 2021, mientras Brasil enfrentaba una de las peores oleadas de muertes por coronavirus, el presidente Jair Bolsonaro anunció el desarrollo de una vacuna nacional y la inminente cooperación científica con Israel. Sin embargo, la agencia reguladora brasileña ANVISA contradijo públicamente las afirmaciones de funcionarios del gobierno, señalando que ninguna de las vacunas en cuestión había superado aún las pruebas en animales. El episodio revela una tensión tan antigua como la política misma: la distancia que puede abrirse entre lo que el poder proclama y lo que la realidad científica sostiene.
- Brasil acumulaba decenas de miles de muertes por COVID-19 cuando Bolsonaro anunció, con tono triunfal, que el país tenía una vacuna propia en camino y resultados listos para compartir con Israel.
- El secretario de Ciencia y Tecnología afirmó que tres candidatas vacunales estaban a punto de iniciar ensayos clínicos en humanos al mes siguiente, generando expectativas en un país desesperado por soluciones.
- ANVISA desmintió de forma directa esas declaraciones: ninguna solicitud formal de ensayos en humanos había llegado a la agencia, y todas las vacunas seguían en fase preclínica con animales.
- La contradicción entre el discurso oficial y la realidad regulatoria quedó expuesta ante la opinión pública, poniendo en entredicho la credibilidad del gobierno en su gestión de la pandemia.
- La pregunta que quedó flotando no era solo sobre vacunas, sino sobre hasta qué punto el mensaje político estaba corriendo más rápido que la ciencia en uno de los momentos más oscuros de Brasil.
A comienzos de marzo de 2021, con el número de muertos por coronavirus en ascenso, el presidente Jair Bolsonaro anunció que Brasil desarrollaba su propia vacuna y que una delegación encabezada por el canciller Ernesto Araújo viajaría a Tel Aviv para compartir los resultados preliminares con Israel. El viaje, según Bolsonaro, serviría para intercambiar protocolos y forjar acuerdos científicos que pudieran beneficiar tanto la crisis inmediata como el futuro del país.
Marcelo Morales, secretario de investigación del Ministerio de Ciencia y Tecnología, aportó detalles concretos: quince proyectos de vacunas estaban en marcha en universidades brasileñas, tres de ellos en etapas avanzadas. Morales aseguró que esas tres candidatas podrían adaptarse rápidamente ante nuevas mutaciones del virus y que estaban listas para iniciar ensayos en humanos el mes siguiente. Añadió que una de ellas ya había sido presentada ante ANVISA, la agencia reguladora de salud del país.
La corrección no tardó en llegar. ANVISA aclaró públicamente que no había recibido ninguna solicitud formal para autorizar pruebas en humanos con ninguna de las tres vacunas. La agencia confirmó que mantenía contacto con centros de investigación universitarios, pero que todos los trabajos permanecían en fase preclínica, es decir, con pruebas aún realizadas en animales.
La brecha entre lo que el gobierno proclamaba y lo que el organismo regulador certificaba quedó al descubierto, planteando preguntas incómodas sobre la transparencia del manejo oficial de la pandemia en uno de los momentos más críticos de la historia sanitaria de Brasil.
In early March 2021, as Brazil grappled with a surging coronavirus death toll, President Jair Bolsonaro announced that his government was developing a homegrown vaccine and would soon share preliminary research findings with Israel. A delegation led by Foreign Minister Ernesto Araújo was preparing to depart for Tel Aviv to discuss scientific cooperation on the pandemic, Bolsonaro said in a video posted to Twitter. The trip, he explained, would focus on exchanging protocols and forging agreements in science and technology that could benefit Brazil's immediate crisis and its future.
What Bolsonaro did not clarify—at least not in his public statement—was the actual status of the Brazilian vaccine effort. Weeks earlier, he had mentioned an experimental nasal spray originally developed for cancer treatment that was still in preliminary studies but might help fight COVID-19. That detail vanished from his Saturday announcement. Instead, he pivoted to a broader claim: Brazil possessed "a vaccine in development," and the delegation would carry the initial results of domestic pharmaceutical research to Israel.
Marcelo Morales, the secretary of research and scientific training at Brazil's Ministry of Science and Technology, offered more specifics. The country's universities were pursuing fifteen separate vaccine projects, he said. Three of those candidates had advanced further than the others and would be the focus of discussions in Israel. Morales suggested the three leading vaccines could adapt quickly if new virus mutations emerged in Brazil. He also stated that all three were expected to enter human clinical trials the following month, and claimed that one had already been submitted to Anvisa, Brazil's national health surveillance agency.
That claim unraveled almost immediately. Anvisa issued a public correction, stating it had received no formal requests to authorize human trials for any of the three vaccines. The agency confirmed it was in contact with research centers at various universities, but all work remained in the preclinical phase—meaning tests were still being conducted on animals, not people. The vaccines had not advanced to the point where researchers could legally begin testing them on human subjects in Brazil.
The contradiction exposed a gap between what government officials were saying publicly and what the country's own regulatory body knew to be true. Bolsonaro and his team were promoting Brazil's vaccine development as imminent and ready to share with international partners. Anvisa was saying the work was still in early stages, with no pathway to human testing yet approved. The discrepancy raised a fundamental question about the credibility of Brazil's vaccine timeline and the degree to which political messaging was outpacing scientific reality during one of the nation's darkest public health moments.
Notable Quotes
The objective of this trip is to seek protocols and agreements in science and technology that will be very beneficial for the virus situation we are living through, as well as a legacy for the future.— President Jair Bolsonaro, in a video statement
Anvisa has not received any formal request to authorize studies in humans in Brazil for these three vaccines.— Brazil's National Health Surveillance Agency (Anvisa), in a public correction
The Hearth Conversation Another angle on the story
Why would Bolsonaro announce vaccine progress that his own health regulator immediately contradicted?
It's worth separating what he was trying to do from what was actually happening. He needed to show Brazil was acting, that it had a plan. Announcing fifteen projects, three in advanced stages—that sounds like momentum.
But Anvisa said they were still testing on animals. That's not advanced.
Right. So either the government was using "advanced" to mean something different than Anvisa does, or officials genuinely believed the vaccines were further along than they were. Either way, the public heard one story and the regulator had to correct it.
Did the delegation actually go to Israel with these results?
The article doesn't say whether the trip happened or what came of it. We know it was planned. But once Anvisa contradicted the claims, the whole premise—sharing preliminary results—became murky.
What does this tell us about Brazil's vaccine effort?
That it existed, but it was fragile. Fifteen projects sounds ambitious. But if three of them weren't even ready for human trials, the timeline Bolsonaro was advertising was fiction. The real work was still years away, probably.